Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer

被引：0
|
作者：
Modi, Shanu
Pusztai, Lajos
Forero, Andres
Mita, Monica
Miller, Kathy D.
Weise, Amy
Krop, Ian
Burris, Howard, III
Kalinsky, Kevin
Tsai, Michaela
Liu, Minetta C.
Hurvitz, Sara A.
Wilks, Sharon
Ademuyiwa, Foluso
Diab, Sami
Han, Hyo S.
Kato, Giraldo
Nanda, Rita
O'Shaughnessy, Joyce
Kostic, Ana
Li, Martha
Specht, Jennifer
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[5] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[6] Karmanos Canc Inst, Detroit, MI USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[9] Columbia Univ, Med Ctr, New York, NY USA
[10] Allina Hlth, Virginia Piper Canc Inst, Minneapolis, MN USA
[11] Mayo Clin, Rochester, MN USA
[12] Univ Calif Los Angeles, Los Angeles, CA USA
[13] Texas Oncol, San Antonio, TX USA
[14] Washington Univ, St Louis, MO USA
[15] US Oncol Denver, Denver, CO USA
[16] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[17] Virginia G Piper Canc Care Network, Scottsdale, AZ USA
[18] Univ Chicago, Chicago, IL 60637 USA
[19] Baylor Univ, Med Ctr, Waco, TX 76798 USA
[20] US Oncol, Texas Oncol, Dallas, TX USA
[21] Seattle Genet Inc, Bothell, WA USA
[22] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-14
引用
收藏
页数：1
相关论文
共 50 条
  • [21] New Perspectives in metastatic triple-negative Breast Cancer Approval of the first-in-class Antibody-Drug Conjugate Sacituzumab Govitecan
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (03) : 142 - 142
  • [22] LIV-1 antibody-drug conjugate: A novel therapeutic agent for breast and prostate cancer
    Sussman, Django
    Nesterova, Albina
    Westendorf, Lori
    Duniho, Steven
    Anderson, Martha
    Mbow, Brianna
    Gregoire, Ashley
    Hunter, Joshua H.
    Whiting, Nancy
    Corey, Eva
    Vessella, Robert L.
    Benjamin, Dennis R.
    Smith, Leia M.
    CANCER RESEARCH, 2011, 71
  • [23] IMPACT OF ITRACONAZOLE ON THE SURVIVAL OF HEAVILY PRETREATED PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
    Tsubamoto, H.
    Inoue, K.
    Sonoda, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1036 - 1036
  • [24] Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer
    Fenn, Kathleen
    Maurer, Matthew
    Lee, Shing M.
    Crew, Katherine D.
    Trivedi, Meghna S.
    Accordino, Melissa K.
    Hershman, Dawn L.
    Kalinsky, Kevin
    CLINICAL BREAST CANCER, 2020, 20 (01) : 80 - 86
  • [25] Efficacy and safety of metronoinc capecitabine and gefitinib in heavily pretreated metastatic triple-negative breast cancer
    Ranade, Anantbhushan
    Babu, Kanaka Govind
    Parikh, Purvish M.
    Singh, Jk
    Singh, Manisha
    Bhattacharyya, Gouri Shankar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs
    Tang, Qi
    Li, Hui
    Zhao, Xin Tong
    Li, Ze Ying
    Ma, Chun Xiao
    Zhou, Shao Qiang
    Chen, De Dian
    WORLD JOURNAL OF ONCOLOGY, 2024, 15 (04) : 527 - 542
  • [27] Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer
    Schipilliti, Francesca Matilde
    Drittone, Denise
    Mazzuca, Federica
    La Forgia, Daniele
    Guven, Deniz Can
    Rizzo, Alessandro
    HELIYON, 2024, 10 (07)
  • [28] MULTICENTER PHASE II STUDY OF APATINIB, A NOVEL INHIBITOR OF VEGFR, IN HEAVILY PRETREATED PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER
    Hu, Xi-chun
    Zhang, Jian
    Xu, Bing-he
    Jiang, Ze-fei
    Tong, Zhong-sheng
    Zhang, Qing-yuan
    Wang, Xiao-jia
    Feng, Ji-feng
    Pang, Dan-mei
    Fan, Min-hao
    Li, Jin
    Wang, Bi-yun
    Wang, Zhong-hua
    Zhang, Qun-ling
    Sun, Si
    Liao, Chun-mei
    Jiang, Hao-yuan
    Shao, Zhi-min
    BREAST, 2013, 22 : S33 - S33
  • [29] A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes
    Li, Qiao
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Luo, Yang
    Fan, Ying
    Cai, Ruigang
    Xu, Binghe
    CANCER BIOLOGY & THERAPY, 2015, 16 (12) : 1746 - 1753
  • [30] A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes
    Li, Qiao
    Xu, Binghe
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Luo, Yang
    Fan, Ying
    Cai, Ruigang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345